title: Sphingosine kinase 1 is a relevant molecular target in gastric cancer.
abstract: Sphingosine kinase 1 (Sphk1), a lipid kinase implicated in cell transformation and tumor growth, is overexpressed in gastric cancer and is linked with a poor prognosis. The biological relevance of Sphk1 expression in gastric cancer is unclear. Here, we studied the functional significance of Sphk1 as a novel molecular target for gastric cancer by using an antisense oligonucleotide approach in vitro and in vivo. Gastric cancer cell lines (MKN28 and N87) were treated with Sphk1 with locked nucleic acid-antisense oligonucleotides (LNA-ASO). Sphk1 target regulation, cell growth, and apoptosis were assessed for single-agent Sphk1 LNA-ASO and for combinations with doxorubicin. Athymic nude mice xenografted with gastric cancer cells were treated with Sphk1 LNA and assessed for tumor growth and Sphk1 target regulation, in vivo. In vitro, nanomolar concentrations of Sphk1 LNA-ASO induced an approximately two-fold reduction in Sphk1 mRNA in both the cell lines. This resulted in a 1.6-fold increase in apoptosis and inhibited the growth of gastric cancer cells by more than 50% (P < 0.05). The combination of Sphk1 LNA-ASO with doxorubicin resulted in significant chemosensitization. In vivo, Sphk1 LNA-ASO displayed neither mRNA target regulation in xenografts nor antitumor activity in two independent nude mouse xenograft models. In conclusion, the potent single-agent activity and the synergistic effect of Sphk1 LNA-ASO in combination with chemotherapy in vitro highlight Sphk1 as a biologically relevant molecular target for gastric cancer. Further studies are warranted to overcome the challenge of delivering Sphk1-targeting RNA-therapeutics to solid tumors in vivo.
authors.affiliation: Department of Clinical Pharmacology, Medical University, Vienna, Austria.
authors.forename: Thorsten
authors.initials: T
authors.lastname: Fuereder
authors.forename: Doris
authors.initials: D
authors.lastname: Hoeflmayer
authors.forename: Agnes
authors.initials: A
authors.lastname: Jaeger-Lansky
authors.forename: Doris
authors.initials: D
authors.lastname: Rasin-Streden
authors.forename: Sabine
authors.initials: S
authors.lastname: Strommer
authors.forename: Niels
authors.initials: N
authors.lastname: Fisker
authors.forename: Bo J
authors.initials: BJ
authors.lastname: Hansen
authors.forename: Richard
authors.initials: R
authors.lastname: Crevenna
authors.forename: Volker
authors.initials: V
authors.lastname: Wacheck
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D015536:Down-Regulation; D004317:Doxorubicin / Q000494:pharmacology; D004357:Drug Synergism; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D058990:Molecular Targeted Therapy; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000235:genetics* / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics; D014162:Transfection; D000099157:Sphingosine Kinase
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; D016376:Oligonucleotides, Antisense; D017853:Phosphotransferases (Alcohol Group Acceptor); D000099157:Sphingosine Kinase